Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind trial of ibuzatrelvir vs remdesivir in severely immunocompromised adults with symptomatic COVID-19
jRCT2071250034Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ibuzatrelvir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Pfizer. Primary endpoint: Primary composite endpoint: clinical outcomes and recurrent/persistent SARS-CoV-2 infection. Started Jul 2025; status: recruiting.
02
Drugs
ibuzatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071250034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250034.